Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.
Clegg
A
A
Wessex Institute for Health Research and Development, University of Southampton, UK.
Bryant
J
J
Milne
R
R
D000276:Adjuvants, Immunologic / Q000191:economics / Q000627:therapeutic use; D001379:Azathioprine / Q000191:economics / Q000627:therapeutic use; D017338:Cladribine / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003520:Cyclophosphamide / Q000191:economics / Q000627:therapeutic use; D016527:Drug Costs / Q000706:statistics & numerical data; D000068717:Glatiramer Acetate; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000191:economics / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000191:economics / Q000627:therapeutic use*; D016899:Interferon-beta / Q000191:economics / Q000627:therapeutic use; D008727:Methotrexate / Q000191:economics / Q000627:therapeutic use; D008942:Mitoxantrone / Q000191:economics / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy*; D010455:Peptides / Q000191:economics / Q000627:therapeutic use; D012107:Research Design / Q000592:standards; D013673:Technology Assessment, Biomedical; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D010455:Peptides; D017338:Cladribine; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D003520:Cyclophosphamide; D008942:Mitoxantrone; D001379:Azathioprine; D008727:Methotrexate